SAR441566 Clinical Trials (2026): 7 Studies for Rheumatoid Arthritis & Psoriasis
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
7 SAR441566 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 4 indications (including Rheumatoid Arthritis & Psoriasis) and 1,057 total planned enrollment. Most recent activity: NCT06867094 (Oct 2026).
SAR441566 clinical trials at a glance: phase × recruitment status
| Phase | active not recruiting | completed | Total |
|---|---|---|---|
| P1 | 3 | 3 | |
| P2 | 2 | 2 | 4 |
SAR441566 clinical trials by indication
Rheumatoid Arthritis (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06073093 | SPECIFI-RA | P2 | completed | A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis |
| NCT05844735 | — | P1 | completed | A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566 |
| NCT05858788 | — | P1 | completed | A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants. |
Psoriasis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06073119 | SPECIFI-PSO | P2 | completed | A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis |
| NCT05453942 | — | P1 | completed | A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis |
Colitis Ulcerative (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06867094 | SPECIFI-UC | P2 | active not recruiting | A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis |
Crohn's Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06637631 | SPECIFI-CD | P2 | active not recruiting | A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. |
SAR441566 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| SPECIFI-UC | NCT06867094 | P2 | active not recruiting | Colitis Ulcerative | 204 | — |
| SPECIFI-CD | NCT06637631 | P2 | active not recruiting | Crohn's Disease | 260 | — |
| SPECIFI-RA | NCT06073093 | P2 | completed | Rheumatoid Arthritis | 264 | — |
| SPECIFI-PSO | NCT06073119 | P2 | completed | Psoriasis | 221 | — |
All SAR441566 trials (7)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06867094 | SPECIFI-UC | A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis | P2 | active not recruiting | 204 | Sanofi | Mar 2025 |
| NCT06637631 | SPECIFI-CD | A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. | P2 | active not recruiting | 260 | Sanofi | Dec 2024 |
| NCT06073093 | SPECIFI-RA | A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis | P2 | completed | 264 | Sanofi | Nov 2023 |
| NCT06073119 | SPECIFI-PSO | A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis | P2 | completed | 221 | Sanofi | Oct 2023 |
| NCT05844735 | A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566 | P1 | completed | 60 | Sanofi | May 2023 | |
| NCT05858788 | A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants. | P1 | completed | 10 | Sanofi | May 2023 | |
| NCT05453942 | A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis | P1 | completed | 38 | Sanofi | Jul 2022 |
SAR441566 clinical trials: frequently asked questions
- How many SAR441566 clinical trials are there?
- 7 SAR441566 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are marked completed.
- Are SAR441566 clinical trials recruiting in 2026?
- No active SAR441566 trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is SAR441566 being studied for?
- SAR441566 is being studied for Rheumatoid Arthritis, Psoriasis, Colitis Ulcerative, Crohn's Disease. The trials are grouped by indication on this page.
- What phase is SAR441566 in?
- SAR441566 clinical trials span 4 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors SAR441566 clinical trials?
- The lead sponsor across the most SAR441566 trials is Sanofi. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming SAR441566as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: